10-Q: Fortive Q3: Core Revenue Growth Amid Strategic Spin-Off

Fortive reports a 2.3% increase in Q3 2025 total sales from continuing operations, driven by favorable pricing and strategic debt reduction following the Ralliant spin-off.

Summary

• Total sales from continuing operations increased by 2.3% to $1,027.1 million for the three months ended September 26, 2025, compared to $1,003.7 million in the prior year period.
• Core revenue growth (non-GAAP) was 1.9% for the third quarter and 1.1% for the nine months ended September 26, 2025, driven by favorable pricing of 2.6% and 2.3% respectively, partially offset by volume declines.
• Net earnings from continuing operations increased to $117.0 million ($0.35 diluted EPS) for the third quarter and $341.2 million ($1.00 diluted EPS) for the nine months ended September 26, 2025, up from $111.5 million ($0.32 diluted EPS) and $289.3 million ($0.82 diluted EPS) in the comparable prior year periods.
• Operating profit from continuing operations decreased to $159.6 million (15.5% margin) for the third quarter and $494.7 million (16.3% margin) for the nine months ended September 26, 2025, compared to $172.0 million (17.1% margin) and $504.1 million (16.8% margin) in the prior year periods.
• Net earnings (loss) from discontinued operations was a loss of $62.0 million for the third quarter and a gain of $52.3 million for the nine months ended September 26, 2025, a significant decrease from $110.1 million and $334.8 million respectively in the prior year periods.
• The Precision Technologies (PT) segment was separated as Ralliant Corporation on June 28, 2025, and is reported as discontinued operations.
• Cash and equivalents decreased to $430.8 million as of September 26, 2025, from $813.3 million at December 31, 2024.
• Long-term debt decreased to $2,117.1 million as of September 26, 2025, from $3,331.1 million at December 31, 2024, primarily due to debt repayments using proceeds from the Ralliant Dividend.
• Repurchased 20.8 million shares of common stock for approximately $1,000 million in the third quarter and 25.2 million shares for approximately $1,345 million year-to-date, including $426 million from the Ralliant Dividend.

Sentiment

Score: 6

Explanation: While continuing operations show positive trends in sales and net earnings, supported by strategic debt reduction and significant share repurchases, the decline in operating profit and margins, coupled with the substantial loss from discontinued operations and ongoing restructuring, presents a mixed operational picture. The strategic spin-off is complete, but the full impact and future growth trajectory require ongoing monitoring.

Positives

• Net earnings from continuing operations increased by 4.9% to $117.0 million in Q3 2025 and by 17.9% to $341.2 million year-to-date.
• Diluted EPS from continuing operations increased to $0.35 in Q3 2025 and $1.00 year-to-date.
• Total sales from continuing operations grew by 2.3% in Q3 2025 and 0.9% year-to-date, driven by favorable pricing.
• Core revenue growth (non-GAAP) was 1.9% in Q3 2025 and 1.1% year-to-date, indicating underlying business strength.
• Interest expense, net, decreased significantly to $25.4 million in Q3 2025 and $89.5 million year-to-date, reflecting reduced outstanding debt and lower interest rates.
• Other non-operating income, net, improved substantially to a gain of $0.8 million in Q3 2025 and $3.1 million year-to-date, compared to losses in the prior year.
• The Intelligent Operating Solutions (IOS) segment reported a 2.6% sales increase and a 110 basis point increase in operating profit margin to 25.9% in Q3 2025.
• The Advanced Healthcare Solutions (AHS) segment reported a 1.9% sales increase and a 150 basis point increase in operating profit margin to 12.9% in Q3 2025.
• Received a $1.15 billion cash dividend from Ralliant Corporation in connection with the Separation, which was used for debt reduction and share repurchases.
• Reduced long-term debt by approximately $1.2 billion from December 31, 2024, to September 26, 2025, utilizing proceeds from the Ralliant Dividend.
• Repurchased a significant number of common shares (20.8 million in Q3, 25.2 million year-to-date), returning capital to shareholders.

Negatives

• Operating profit from continuing operations decreased by 7.2% to $159.6 million in Q3 2025 and by 1.9% to $494.7 million year-to-date.
• Operating profit margin from continuing operations declined by 160 basis points to 15.5% in Q3 2025 and by 50 basis points to 16.3% year-to-date.
• Volume declined by 0.7% in Q3 2025 and 1.2% year-to-date, partially offsetting favorable pricing.
• Net earnings from discontinued operations resulted in a loss of $62.0 million in Q3 2025, a significant negative swing from a $110.1 million gain in the prior year.
• Cash and equivalents decreased by $382.5 million during the nine months ended September 26, 2025.
• Higher income tax expense of $18.0 million in Q3 2025 compared to a $2.4 million benefit in the prior year, and $67.1 million year-to-date compared to $36.8 million.
• The restructuring plan, initiated in Q4 2024, has been extended through the second half of 2026, indicating ongoing operational adjustments.
• The AHS segment experienced modest volume declines in sterilization equipment due to uncertainty surrounding hospital responses to recent changes in healthcare policy.

Risks

• Conditions in the global economy, the markets served, and financial markets may adversely affect business and financial results.
• Inability to adjust manufacturing capacity, supply chain management, or purchases to reflect changes in market conditions, international trade policies, customer demand, government shutdowns, and supply chain disruptions could harm profitability.
• Reliance upon sole or limited sources of supply for certain materials, components, and services could cause production interruptions, delays, and inefficiencies.
• Financial results are subject to fluctuations in the cost and availability of commodities or components.
• Growth could suffer if markets decline, do not grow as anticipated, or experience cyclicality.
• Intense competition may lead to decreased demand, market share, or require price reductions.
• Growth depends on timely development, commercialization, and customer acceptance of new products and services based on technological innovation.
• Ability to attract, develop, and retain senior leaders and other key employees is critical to success.
• Disruptions in, or breaches in security of, information technology systems could adversely affect the business.
• Defects and unanticipated use or inadequate disclosure with respect to products (including software) or services could adversely affect business, reputation, and financial results.
• Adverse changes in relationships with, or the financial condition, performance, purchasing patterns, or inventory levels of, key distributors and other channel partners could adversely affect financial results.
• Restructuring activities could have long-term adverse effects on the business.
• Work stoppages, works council campaigns, and other labor disputes could adversely impact productivity and results of operations.
• Loss to facilities, supply chains, distribution systems, or information technology systems due to catastrophe or other events could seriously harm operations.
• Inability to adequately protect intellectual property, or infringement by third parties, may lead to competitive injury or significant enforcement resources.
• Third parties may claim infringement or misappropriation of their intellectual property rights, leading to significant litigation expenses, losses, or licensing expenses, or preventing product/service sales.
• Subject to a variety of litigation and other legal and regulatory proceedings that could adversely affect financial results.
• Climate change, or legal/regulatory measures to address it, may negatively affect the company.
• Challenges with properly managing the use of artificial intelligence in business and products could result in reputational harm, competitive harm, and legal liability.
• International economic, political, legal, trade policies, compliance, and business factors could negatively affect financial results.
• Trade relations between the United States and other countries, including tariffs and related uncertainty, could have a material adverse effect on business and financial results.
• Foreign currency exchange rates, including volatility, may adversely affect financial results.
• Inability to consummate acquisitions at appropriate prices, and to make appropriate investments and capital allocation, could negatively impact growth rate and stock price.
• Acquisition of businesses, investments, joint ventures, and other strategic relationships could negatively impact financial results.
• Indemnification provisions of acquisition agreements may not fully protect the company from unexpected liabilities.
• Divestitures or other dispositions could negatively impact the business, and contingent liabilities from sold businesses could adversely affect financial results.
• Potential indemnification liabilities to Ralliant Corporation and Vontier Corporation pursuant to separation agreements could materially and adversely affect businesses, financial condition, results of operations, and cash flows.
• Changes in industry standards and governmental regulations may reduce demand for products/services or increase expenses.
• Reputation, ability to do business, and financial results may be impaired by improper conduct by employees, agents, or business partners.
• Operations, products, and services expose the company to environmental, health, and safety liabilities, costs, and violations.
• Businesses are subject to extensive regulation, including healthcare regulations; failure to comply could adversely affect financial results and reputation.
• Changes in effective tax rates or exposure to additional tax liabilities or assessments could affect profitability, and tax audits could result in additional payments.
• Could incur significant liability if separation transactions (Danaher, Automation and Specialty, Vontier, Ralliant) are determined to be taxable.
• Changes in U.S. GAAP could adversely affect reported financial results and require significant changes to internal accounting systems.
• May be required to recognize impairment charges for goodwill and other intangible assets.
• Incurred a significant amount of debt, and debt obligations will increase if additional debt is incurred, existing debt is not retired, credit rating declines, or interest rates rise.

Future Outlook

The financial outlook is subject to various assumptions and risks, including ongoing geopolitical events, global economic and consumer trends, monetary policies, inflationary pressures, governmental policies on international trade, regulations, sanctions, and healthcare, prolonged government shutdowns, operational challenges from tariffs, foreign exchange rate volatility, U.S. government spending (H.R.1), the OECD Pillar Two initiative, and the impact from the Ralliant Separation. The company expects to have sufficient liquidity to satisfy cash needs for the foreseeable future and continues to monitor conditions and deploy the Fortive Business System (FBS) to manage challenges and optimize operations, including pricing, cost, and productivity actions.

Management Comments

• Fortive Corporation innovates essential technologies to keep the world safe and productive.
• Our strategic segments Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) include iconic inventor brands with leading positions in their markets.
• We continue to monitor the conditions above and deploy the Fortive Business System (FBS), including tools and processes to leverage existing sourcing strategies and optimize production and logistics to actively manage these challenges and utilize pricing, cost and productivity actions and other countermeasures designed to offset the aforementioned dynamics.

Industry Context

Fortive operates in a highly competitive business environment across its Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) segments. Long-term growth and profitability depend on expanding across geographies and market segments, strategic acquisitions, developing innovative products and services, enhancing sales force effectiveness, reducing costs, improving operating efficiency, attracting and retaining talent, and navigating an increasingly regulated environment. The Advanced Healthcare Solutions segment specifically noted reduced demand for sterilization equipment due to uncertainty surrounding hospital responses to recent changes in healthcare policy, indicating sensitivity to regulatory and policy shifts in the healthcare sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or global benchmarks to assess results against industry standards. Analysis would require external industry data and competitor performance metrics not included in this document.

Corporate Governance

Legal Proceedings

• The company is subject to a variety of litigation and other legal and regulatory proceedings in the course of its business that could adversely affect financial results. No new material proceedings were detailed in this filing.

Related Party Transactions

• A charitable contribution was made to the Fortive Foundation, a related party, in the first quarter of 2024.
• Agreements with Ralliant Corporation (a former segment, now a separate entity) are considered related party transactions, including the $1.15 billion cash dividend received by Fortive from Ralliant.

Stakeholder Impact

• Shareholders: Received Ralliant common stock in the spin-off, benefited from significant share repurchases ($1.345 billion year-to-date), and received quarterly dividends ($0.06 per share in Q3 2025). Impacted by improved net earnings from continuing operations but also by the loss from discontinued operations.
• Employees: Subject to targeted workforce reductions as part of the discrete restructuring plan. Stock-based compensation adjustments occurred due to the Separation and executive retirements.
• Customers: Continue to be served by the Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) segments, with ongoing investments in innovation and customer-facing resources.
• Creditors: Benefited from significant debt repayments ($715.7 million year-to-date) using proceeds from the Ralliant Dividend, reducing overall debt exposure.
• Suppliers: Impacted by ongoing supply chain management and sourcing strategies, as the company actively manages challenges and optimizes production.

Next Steps

• Complete the discrete restructuring plan, which has been extended through the second half of 2026.
• Monitor further guidance and legislative developments related to the OECD Pillar Two framework.
• Continue to monitor financial markets, the stability of U.S. and international banks, and general global economic conditions.
• Deploy the Fortive Business System (FBS) tools and processes to leverage existing sourcing strategies and optimize production and logistics.
• Utilize pricing, cost, and productivity actions and other countermeasures to offset dynamic economic and trade challenges.
• Continue making significant investments, organically and through acquisitions, to address technological change and improve resources.

Key Dates

Recommendation

Fortive's Q3 2025 results present a mixed picture. While continuing operations show positive momentum with core revenue growth and increased net earnings per share, the decline in overall operating profit and margins, coupled with volume softness, warrants caution. The strategic spin-off of Ralliant and the subsequent significant debt reduction and share repurchases are positive capital allocation moves that streamline the business and return value to shareholders. However, the substantial loss from discontinued operations and the extended restructuring plan indicate ongoing operational adjustments. A 'Hold' recommendation is appropriate as investors should monitor the company's ability to translate its strategic repositioning into sustained operating profit growth and improved volumes in its core segments, especially given the noted demand uncertainty in parts of the Advanced Healthcare Solutions segment.

Keywords

Fortive, FTV, Quarterly Report, SEC Filing, 10-Q, Intelligent Operating Solutions, Advanced Healthcare Solutions, IOS, AHS, Ralliant, Spin-off, Discontinued Operations, Core Revenue, Financial Results, Debt Management, Share Repurchase, Healthcare, Industrial, Manufacturing, Software, Services, Technology, Operating Profit, EPS, Capital Allocation